Company Overview

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutics that address unmet needs in pain management and oncology supportive care. The company operates primarily within the biopharmaceutical industry, with an emphasis on acute care and post-surgical recovery products. Heron’s revenue is primarily derived from sales of FDA-approved products used in hospital, ambulatory surgery center, and oncology treatment settings.

Heron’s core commercial portfolio includes ZYNRELEF, an extended-release local anesthetic for post-operative pain management; CINVANTI and SUSTOL, which are used to prevent chemotherapy-induced nausea and vomiting; and APONVIE, an injectable antiemetic therapy. The company has positioned itself around differentiated drug-delivery technologies intended to improve efficacy, reduce opioid use, and simplify treatment protocols. Founded in 1983 and formerly known as A.P. Pharma, Inc., the company adopted the Heron Therapeutics name in 2013 as it expanded beyond its original oncology-supportive-care focus into acute pain therapeutics.

Business Operations

Heron generates revenue primarily through the commercialization of branded pharmaceutical products in the United States. The company’s business is centered on two major therapeutic categories: oncology supportive care and acute pain management. Its commercial operations target hospitals, surgical centers, anesthesiologists, surgeons, oncologists, and institutional healthcare providers. According to public filings, the company operates largely through a single reportable business segment focused on pharmaceutical development and commercialization.

The company controls several proprietary formulation and drug-delivery technologies designed to extend therapeutic duration and improve administration profiles. ZYNRELEF incorporates Heron’s bioerodible polymer-based delivery platform for sustained local anesthetic release. Heron also maintains commercial and manufacturing relationships with third-party pharmaceutical manufacturers and distributors to support production and supply chain operations. While the majority of revenue has historically been generated in the United States, certain products have had licensing or distribution arrangements outside the U.S., though international commercialization remains more limited compared with larger multinational pharmaceutical companies.

Strategic Position & Investments

Heron’s strategic direction has focused on expanding adoption of its acute care and oncology-supportive-care portfolio while pursuing lifecycle management opportunities and label expansions for existing products. A major strategic initiative has been the commercial rollout and expanded utilization of ZYNRELEF, particularly as healthcare systems seek alternatives to opioid-based post-surgical pain management. The company has also invested in expanding its acute-care sales infrastructure and physician engagement efforts.

In 2022, Heron acquired Acuity Bio Corp., strengthening its development capabilities and intellectual property position in acute-care therapeutics. The company continues to invest in differentiated formulations and perioperative care solutions that align with broader healthcare trends emphasizing enhanced recovery protocols and reduced opioid exposure. Public disclosures indicate that Heron’s strategy emphasizes targeted commercialization in specialized healthcare settings rather than broad primary-care pharmaceutical markets.

Geographic Footprint

Heron Therapeutics is headquartered in San Diego, California, and conducts the majority of its commercial activities within the United States. Its products are marketed primarily to U.S. hospitals, oncology clinics, and ambulatory surgery centers. The company’s operational infrastructure includes commercial, regulatory, medical affairs, and development functions concentrated domestically.

Although Heron has had certain international licensing relationships and intellectual property protections extending into multiple global jurisdictions, its direct operational footprint outside North America remains comparatively limited. The company’s market influence is therefore strongest in the U.S. acute-care and oncology-supportive-care sectors, where regulatory approvals from the U.S. Food and Drug Administration have been central to commercialization efforts.

Leadership & Governance

Heron Therapeutics is led by an executive management team with backgrounds in biotechnology commercialization, pharmaceutical development, and healthcare operations. The company’s governance structure includes a board of directors responsible for oversight of corporate strategy, financial controls, risk management, and shareholder interests. Leadership communications in public filings and investor presentations have emphasized disciplined commercialization, product adoption growth, and expansion within non-opioid pain management markets.

Key executives include:

• Craig A. Collard – Chief Executive Officer
• Alan S. Marcus – Chief Financial Officer
• Mark H.N. Corrigan, M.D. – Director and former Executive Chairman
• Ryan D. Lake – Chief Commercial Officer
• Jonathan B. Leff, M.D. – Chief Medical Officer

The company’s leadership strategy has consistently emphasized execution in hospital-based pharmaceutical markets, portfolio optimization, and leveraging differentiated drug-delivery technologies to compete within specialized therapeutic categories.